These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
474 related articles for article (PubMed ID: 19570025)
41. Leucine-rich repeat kinase 2 binds to neuronal vesicles through protein interactions mediated by its C-terminal WD40 domain. Piccoli G; Onofri F; Cirnaru MD; Kaiser CJ; Jagtap P; Kastenmüller A; Pischedda F; Marte A; von Zweydorf F; Vogt A; Giesert F; Pan L; Antonucci F; Kiel C; Zhang M; Weinkauf S; Sattler M; Sala C; Matteoli M; Ueffing M; Gloeckner CJ Mol Cell Biol; 2014 Jun; 34(12):2147-61. PubMed ID: 24687852 [TBL] [Abstract][Full Text] [Related]
42. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Guo L; Gandhi PN; Wang W; Petersen RB; Wilson-Delfosse AL; Chen SG Exp Cell Res; 2007 Oct; 313(16):3658-70. PubMed ID: 17706965 [TBL] [Abstract][Full Text] [Related]
43. Phosphorylation of LRRK2: from kinase to substrate. Lobbestael E; Baekelandt V; Taymans JM Biochem Soc Trans; 2012 Oct; 40(5):1102-10. PubMed ID: 22988873 [TBL] [Abstract][Full Text] [Related]
44. [Advance of the study on LRRK2 gene in Parkinson's disease]. Zhang Y; Chen S Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec; 25(6):657-9. PubMed ID: 19065525 [TBL] [Abstract][Full Text] [Related]
45. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. West AB; Moore DJ; Biskup S; Bugayenko A; Smith WW; Ross CA; Dawson VL; Dawson TM Proc Natl Acad Sci U S A; 2005 Nov; 102(46):16842-7. PubMed ID: 16269541 [TBL] [Abstract][Full Text] [Related]
54. Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily. Stafa K; Tsika E; Moser R; Musso A; Glauser L; Jones A; Biskup S; Xiong Y; Bandopadhyay R; Dawson VL; Dawson TM; Moore DJ Hum Mol Genet; 2014 Apr; 23(8):2055-77. PubMed ID: 24282027 [TBL] [Abstract][Full Text] [Related]
55. Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities. Liu M; Dobson B; Glicksman MA; Yue Z; Stein RL Biochemistry; 2010 Mar; 49(9):2008-17. PubMed ID: 20146535 [TBL] [Abstract][Full Text] [Related]
56. The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. Gandhi PN; Wang X; Zhu X; Chen SG; Wilson-Delfosse AL J Neurosci Res; 2008 Jun; 86(8):1711-20. PubMed ID: 18214993 [TBL] [Abstract][Full Text] [Related]
57. LRRK2 and autophagy: a common pathway for disease. Manzoni C Biochem Soc Trans; 2012 Oct; 40(5):1147-51. PubMed ID: 22988880 [TBL] [Abstract][Full Text] [Related]
58. Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity. Nguyen AP; Moore DJ Adv Neurobiol; 2017; 14():71-88. PubMed ID: 28353279 [TBL] [Abstract][Full Text] [Related]
59. Expression of leucine-rich repeat kinase 2 (LRRK2) inhibits the processing of uMtCK to induce cell death in a cell culture model system. Cui J; Yu M; Niu J; Yue Z; Xu Z Biosci Rep; 2011 Oct; 31(5):429-37. PubMed ID: 21370995 [TBL] [Abstract][Full Text] [Related]
60. ERKed by LRRK2: a cell biological perspective on hereditary and sporadic Parkinson's disease. Verma M; Steer EK; Chu CT Biochim Biophys Acta; 2014 Aug; 1842(8):1273-81. PubMed ID: 24225420 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]